JIIM
MCID: JVN060
MIFTS: 15

Juvenile Idiopathic Inflammatory Myopathy (JIIM)

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Juvenile Idiopathic Inflammatory Myopathy

MalaCards integrated aliases for Juvenile Idiopathic Inflammatory Myopathy:

Name: Juvenile Idiopathic Inflammatory Myopathy 58
Jiim 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare systemic and rhumatological diseases


External Ids:

Orphanet 58 ORPHA329888

Summaries for Juvenile Idiopathic Inflammatory Myopathy

MalaCards based summary : Juvenile Idiopathic Inflammatory Myopathy, also known as jiim, is related to juvenile polymyositis and myopathy. An important gene associated with Juvenile Idiopathic Inflammatory Myopathy is LMNA (Lamin A/C). The drugs rituximab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder.

Related Diseases for Juvenile Idiopathic Inflammatory Myopathy

Diseases related to Juvenile Idiopathic Inflammatory Myopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 juvenile polymyositis 11.3
2 myopathy 10.6
3 myositis 10.3
4 exanthem 10.2
5 dermatomyositis 10.2
6 calcinosis 10.2
7 skin disease 10.2
8 poikiloderma with neutropenia 10.0
9 polymyositis 10.0
10 plica syndrome 10.0
11 childhood type dermatomyositis 10.0
12 synovitis 10.0
13 dyskeratosis congenita 10.0
14 interstitial lung disease 10.0
15 arthritis 10.0
16 lung disease 10.0
17 muscular dystrophy 10.0
18 leukoplakia 10.0
19 overlap myositis 10.0
20 juvenile overlap myositis 10.0

Graphical network of the top 20 diseases related to Juvenile Idiopathic Inflammatory Myopathy:



Diseases related to Juvenile Idiopathic Inflammatory Myopathy

Symptoms & Phenotypes for Juvenile Idiopathic Inflammatory Myopathy

Drugs & Therapeutics for Juvenile Idiopathic Inflammatory Myopathy

Drugs for Juvenile Idiopathic Inflammatory Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 2 174722-31-7 10201696
2 Antineoplastic Agents, Immunological Phase 2
3 Immunologic Factors Phase 2
4 Antirheumatic Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo

Search NIH Clinical Center for Juvenile Idiopathic Inflammatory Myopathy

Genetic Tests for Juvenile Idiopathic Inflammatory Myopathy

Anatomical Context for Juvenile Idiopathic Inflammatory Myopathy

Publications for Juvenile Idiopathic Inflammatory Myopathy

Articles related to Juvenile Idiopathic Inflammatory Myopathy:

(show all 44)
# Title Authors PMID Year
1
Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. 61
32889531 2021
2
Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicenter study. 61
33576399 2021
3
External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort. 61
32810274 2021
4
Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients: Analysis From a Multicentric Cohort in Spain. 61
33492027 2021
5
From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies. 61
33314705 2020
6
Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. 61
33360322 2020
7
Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. 61
33140079 2020
8
Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. 61
32890032 2020
9
Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. 61
31755959 2020
10
Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. 61
31955618 2020
11
Long-term outcomes in Juvenile Myositis patients. 61
31303436 2020
12
Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. 61
30378704 2019
13
Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology. 61
30706861 2019
14
A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy. 61
31001260 2019
15
Juvenile Idiopathic Inflammatory Myopathies. 61
30031496 2018
16
Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals. 61
29673367 2018
17
Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody. 61
29552370 2018
18
Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. 61
29089059 2017
19
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. 61
27894310 2016
20
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. 61
27028907 2016
21
Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis. 61
26966131 2016
22
Juvenile Idiopathic Inflammatory Myopathy in a Patient With Dyskeratosis Congenita Due to C16orf57 Mutation. 61
26535771 2016
23
Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. 61
26338728 2015
24
Efficacy of ultrasound elastography in detecting active myositis in children: can it replace MRI? 61
25903842 2015
25
Infantile-onset LMNA-associated Muscular Dystrophy Mimicking Juvenile Idiopathic Inflammatory Myopathy. 61
26034236 2015
26
Recent advances in juvenile idiopathic inflammatory myopathies. 61
25160931 2014
27
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. 61
24182859 2013
28
An update on inflammatory myositis in children. 61
23912317 2013
29
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. 61
23877355 2013
30
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. 61
23263716 2013
31
Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. 61
20802007 2010
32
Update on the assessment of children with juvenile idiopathic inflammatory myopathy. 61
20425522 2010
33
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. 61
19690132 2009
34
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. 61
17890275 2007
35
Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). 61
16966313 2006
36
Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. 61
16082628 2005
37
Anaerobic exercise capacity in patients with juvenile-onset idiopathic inflammatory myopathies. 61
15818720 2005
38
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. 61
15146430 2004
39
Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. 61
11709612 2001
40
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. 61
11361197 2001
41
Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. 61
11191545 2000
42
Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. 61
10886238 2000
43
Juvenile idiopathic inflammatory myopathies: the value of magnetic resonance imaging in the detection of muscle involvement. 61
10772694 2000
44
Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. 61
9769831 1998

Variations for Juvenile Idiopathic Inflammatory Myopathy

Expression for Juvenile Idiopathic Inflammatory Myopathy

Search GEO for disease gene expression data for Juvenile Idiopathic Inflammatory Myopathy.

Pathways for Juvenile Idiopathic Inflammatory Myopathy

GO Terms for Juvenile Idiopathic Inflammatory Myopathy

Sources for Juvenile Idiopathic Inflammatory Myopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....